Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239587 | 1.00 | HTT (0.44) | HTTTP53LMNAPDE2AKCNH2 | |
| SCHEMBL6742837 | 1.00 | HTT (0.44) | HTTTP53LMNAPDE2AKCNH2 | |
| SCHEMBL30917700 | 1.00 | HTT (0.44) | HTTTP53LMNAPDE2AKCNH2 | |
| SCHEMBL31042467 | 0.83 | MEN1 (0.40) | HTTTP53LMNAPDE2AKCNH2 | |
| SCHEMBL3119255 | 0.83 | MEN1 (0.40) | HTTTP53LMNAPDE2AKCNH2 | |
| SCHEMBL16166567 | 0.83 | MEN1 (0.40) | HTTTP53LMNAPDE2AKCNH2 | |
| SCHEMBL9967737 | 0.83 | LMNA (0.47) | HTTTP53LMNAKCNH2MEN1 | |
| SCHEMBL27567999 | 0.81 | HTT (0.45) | HTTTP53LMNAKCNH2MEN1 | |
| SCHEMBL1345509 | 0.79 | LMNA (0.64) | HTTTP53LMNAPDE2AMEN1 | |
| SCHEMBL6744805 | 0.79 | KCNH2 (0.43) | HTTTP53LMNAPDE2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714661-B1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-9045389-B2 | Biphenyl derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-02 | — | — | US | disclosed |
| EP-2714647-B1 | BIPHENYL DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-8748624-B2 | Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2014-06-10 | — | — | US | disclosed |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| US-20120302641-A1 | BIPHENYL DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012162409-A1 | BIPHENYL DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012162407-A1 | PICOLINAMIDO - PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2012-11-29 | — | — | WO | disclosed |
| CN-101679395-B | Triazolyl aminopyrimidine compounds | LILLY CO ELI | 2012-06-13 | — | — | CN | disclosed |
| US-8063035-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-04-08 | — | — | US | disclosed |
| CN-101679395-A | triazolyl aminopyrimidine compounds | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| EP-2155734-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008144223-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302641-A1 | BIPHENYL DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GPR119, GIPR, GLP1R | HTT 2423/4885TP53 4218/4885LMNA 3449/4885 |
| US-20100087431-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | HTT 3719/4885TP53 2/4885LMNA 4572/4885 |
| US-20120302610-A1 | PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GIPR, GCGR | HTT 1687/4885TP53 3586/4885LMNA 3083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.